KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables: 2017-2025

Historic Receivables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $1.5 billion.

  • Amneal Pharmaceuticals' Receivables rose 20.27% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 12.17%. This contributed to the annual value of $1.3 billion for FY2024, which is 8.51% up from last year.
  • Amneal Pharmaceuticals' Receivables amounted to $1.5 billion in Q3 2025, which was up 8.41% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables peaked at $1.5 billion during Q3 2025, and registered a low of $980.8 million during Q1 2022.
  • Its 3-year average for Receivables is $1.2 billion, with a median of $1.2 billion in 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Receivables decreased by 26.17% in 2021 and then grew by 20.27% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Receivables stood at $1.2 billion in 2021, then climbed by 14.69% to $1.4 billion in 2022, then decreased by 12.20% to $1.2 billion in 2023, then rose by 8.51% to $1.3 billion in 2024, then grew by 20.27% to $1.5 billion in 2025.
  • Its Receivables was $1.5 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.3 billion in Q1 2025.